StonvexLoading…
StonvexStonvexStonvexCore line items from AKBA's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $236.20M | $160.18M | $194.62M | $292.48M |
Operating Income | $23.50M | $-50.47M | $-46.26M | $-80.78M |
Net Income | $-5.34M | $-69.41M | $-51.92M | $-94.23M |
EPS (Diluted) | $-0.02 | $-0.33 | $-0.28 | $-0.52 |
Total Assets | $376.56M | $220.67M | $241.70M | $356.05M |
Total Liabilities | $343.95M | $269.86M | $272.29M | $350.82M |
Cash & Equivalents | $184.84M | $51.87M | $42.92M | $90.47M |
Free Cash Flow OCF − CapEx | $67.70M | $-40.69M | $-23.38M | $-73.27M |
Shares Outstanding | 265.42M | 224.85M | 194.58M | 184.14M |